SRPT
Sarepta Therapeutics, Inc. · Healthcare
Insiders sold $417K of Sarepta Therapeutics, Inc. in the last 12 months and bought none
SRPT over the last year
SRPT after insider buys
3 months after each buy, from the first price a copier could get.
7 buys since 2017 with 3 months of prices.
Congress
Members reported 3 trades in SRPT since 2023.
Every filing
74 insider filings since 2016, newest first
Stephen Mayo · Director
Ian Michael Estepan · COO
Ian Michael Estepan · CFO
Ryan Edward Brown · EVP and General Counsel
Bilal Arif · Chief Tech Ops Officer
Dallan Murray · Chief Customer Officer
Hans Lennart Rudolf Wigzell · Director
Kathryn Jean Boor · Director
Stephen Mayo · Director
Bilal Arif · Chief Tech Ops Officer
Ian Michael Estepan · CFO
Ryan Edward Brown · EVP and General Counsel
Richard Barry · Director
Douglas S Ingram · President and CEO
Michael Andrew Chambers · Director
Michael Andrew Chambers · Director
Michael Andrew Chambers · Director
Hans Lennart Rudolf Wigzell · Director
Stephen Mayo · Director
Michael Andrew Chambers · Director
Michael Andrew Chambers · Director
Douglas S Ingram · President and CEO
M Kathleen Behrens · Director
Hans Lennart Rudolf Wigzell · Director
Joseph Bratica · Principal Financial Officer
Joseph Bratica · Principal Financial Officer
Hans Lennart Rudolf Wigzell · Director
Richard Barry · Director
Joseph Bratica · Principal Financial Officer
David T Howton · EVP and General Counsel
Hans Lennart Rudolf Wigzell · Director
Richard Barry · Director
Hans Lennart Rudolf Wigzell · Director
Alexander Cumbo · EVP and Chief Commercial Officer
David T Howton · EVP and General Counsel
Sandesh Mahatme · EVP, CFO, CBO
David T Howton · EVP and General Counsel
Richard Barry · Director
Michael W Bonney · Director
M Kathleen Behrens · Director
Richard Barry · Director
Richard Barry · Director
Douglas S Ingram · President and CEO
Hans Lennart Rudolf Wigzell · Director
Sandesh Mahatme · EVP, CFO, CBO
Alexander Cumbo · SVP and Chief Commercial Officer
David T Howton · SVP and General Counsel
Sandesh Mahatme · EVP, CFO, CBO
Hans Lennart Rudolf Wigzell · Director
M Kathleen Behrens · Director
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.